Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

A snapshot of medical physics practice patterns.

Kisling KD, Ger RB, Netherton TJ, Cardenas CE, Owens CA, Anderson BM, Lee J, Rhee DJ, Edward SS, Gay SS, He Y, David SD, Yang J, Nitsch PL, Balter PA, Urbauer DL, Peterson CB, Court LE, Dube S.

J Appl Clin Med Phys. 2018 Oct 1. doi: 10.1002/acm2.12464. [Epub ahead of print]

PMID:
30272385
2.

Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling.

Ng SP, Bahig H, Wang J, Cardenas CE, Lucci A, Hall CS, Meas S, Sarli VN, Yuan Y, Urbauer DL, Ding Y, Ikner S, Dinh V, Elgohari BA, Johnson JM, Skinner HD, Gunn GB, Garden AS, Phan J, Rosenthal DI, Morrison WH, Frank SJ, Hutcheson KA, Mohamed ASR, Lai SY, Ferrarotto R, MacManus MP, Fuller CD.

BMC Cancer. 2018 Sep 19;18(1):903. doi: 10.1186/s12885-018-4808-5.

3.

Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial.

Frumovitz M, Plante M, Lee PS, Sandadi S, Lilja JF, Escobar PF, Gien LT, Urbauer DL, Abu-Rustum NR.

Lancet Oncol. 2018 Oct;19(10):1394-1403. doi: 10.1016/S1470-2045(18)30448-0. Epub 2018 Aug 22.

4.

Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.

Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, Meyer LA, Soliman PT, Lu KH, Ramirez PT, Ramondetta L, Bodurka DC, Westin SN.

Obstet Gynecol. 2018 Jan;131(1):109-116. doi: 10.1097/AOG.0000000000002390.

PMID:
29215513
5.

Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.

Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA.

Cancer. 2017 Dec 15;123(24):4823-4831. doi: 10.1002/cncr.30937. Epub 2017 Aug 22.

PMID:
28832979
6.

The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma.

Chéry L, Borregales LD, Fellman B, Urbauer DL, Garg N, Parker N, Katz MHG, Wood CG, Karam JA.

Urology. 2017 Oct;108:114-121. doi: 10.1016/j.urology.2017.05.056. Epub 2017 Jul 10.

7.

CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.

Kurnit KC, Kim GN, Fellman BM, Urbauer DL, Mills GB, Zhang W, Broaddus RR.

Mod Pathol. 2017 Jul;30(7):1032-1041. doi: 10.1038/modpathol.2017.15. Epub 2017 Mar 10.

8.

Nothing left to chance? The impact of locus of control on physical and mental quality of life in terminal cancer patients.

Brown AJ, Thaker PH, Sun CC, Urbauer DL, Bruera E, Bodurka DC, Ramondetta LM.

Support Care Cancer. 2017 Jun;25(6):1985-1991. doi: 10.1007/s00520-017-3605-z. Epub 2017 Feb 7.

9.

Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer.

Bruegl AS, Ring KL, Daniels M, Fellman BM, Urbauer DL, Broaddus RR.

Cancer Prev Res (Phila). 2017 Feb;10(2):108-115. doi: 10.1158/1940-6207.CAPR-16-0219. Epub 2016 Dec 13.

10.

Do No Harm, Except to Ourselves? A Survey of Symptoms and Injuries in Oncologic Surgeons and Pilot Study of an Intraoperative Ergonomic Intervention.

Voss RK, Chiang YJ, Cromwell KD, Urbauer DL, Lee JE, Cormier JN, Stucky CH.

J Am Coll Surg. 2017 Jan;224(1):16-25.e1. doi: 10.1016/j.jamcollsurg.2016.09.013. Epub 2016 Sep 30.

PMID:
27693681
11.

Endometrial Cancer Associated Symptoms: A Case-Control Study.

Pakish JB, Lu KH, Sun CC, Burzawa JK, Greisinger A, Smith FA, Fellman B, Urbauer DL, Soliman PT.

J Womens Health (Larchmt). 2016 Nov;25(11):1187-1192. Epub 2016 Jun 2.

12.

Nurse and patient characteristics predict communication about complementary and alternative medicine.

Spencer CN, Lopez G, Cohen L, Urbauer DL, Hallman DM, Fisch MJ, Parker PA.

Cancer. 2016 May 15;122(10):1552-9. doi: 10.1002/cncr.29819. Epub 2016 Mar 17.

13.

Reply to beta blockers in epithelial ovarian cancer and beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias?

Thaker PH, Urbauer DL, Sood AK.

Cancer. 2016 Jan 15;122(2):325-6. doi: 10.1002/cncr.29723. Epub 2015 Oct 7. No abstract available.

14.

Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.

Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK.

Cancer. 2015 Oct 1;121(19):3444-51. doi: 10.1002/cncr.29392. Epub 2015 Aug 24.

16.

Survivors of gynecologic malignancies: impact of treatment on health and well-being.

Westin SN, Sun CC, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Frumovitz MM, Lu KH, Bodurka DC.

J Cancer Surviv. 2016 Apr;10(2):261-70. doi: 10.1007/s11764-015-0472-9. Epub 2015 Aug 6.

17.

Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment.

Smith JA, Costales AB, Jaffari M, Urbauer DL, Frumovitz M, Kutac CK, Tran H, Coleman RL.

J Oncol Pharm Pract. 2016 Aug;22(4):599-604. doi: 10.1177/1078155215594415. Epub 2015 Jul 15.

PMID:
26183293
18.

Intact PTEN Expression by Immunohistochemistry is Associated With Decreased Survival in Advanced Stage Ovarian/Primary Peritoneal High-grade Serous Carcinoma.

Bakkar RM, Xie SS, Urbauer DL, Djordjevic B, Vu K, Broaddus RR.

Int J Gynecol Pathol. 2015 Nov;34(6):497-506. doi: 10.1097/PGP.0000000000000205.

PMID:
26166715
19.

Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.

Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras González GM, Anderson R, Grossman HB, Prat F, Dinney CP.

Eur Urol. 2016 Feb;69(2):197-200. doi: 10.1016/j.eururo.2015.06.023. Epub 2015 Jun 25. Erratum in: Eur Urol. 2016 Jul;70(1):e26.

20.

Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre.

Zhou C, Urbauer DL, Fellman BM, Tamboli P, Zhang M, Matin SF, Wood CG, Karam JA.

BJU Int. 2016 May;117(5):775-82. doi: 10.1111/bju.13194. Epub 2015 Jul 5.

21.

Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial.

Karam JA, Devine CE, Fellman BM, Urbauer DL, Abel EJ, Allaf ME, Bex A, Lane BR, Thompson RH, Wood CG.

BJU Int. 2016 Apr;117(4):629-35. doi: 10.1111/bju.13188. Epub 2015 Jun 29.

22.

Feeling powerless: Locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients.

Brown AJ, Sun CC, Urbauer DL, Bodurka DC, Thaker PH, Ramondetta LM.

Gynecol Oncol. 2015 Aug;138(2):388-93. doi: 10.1016/j.ygyno.2015.05.005. Epub 2015 May 16.

PMID:
25988961
23.

Overall survival after pelvic exenteration for gynecologic malignancy.

Westin SN, Rallapalli V, Fellman B, Urbauer DL, Pal N, Frumovitz MM, Ramondetta LM, Bodurka DC, Ramirez PT, Soliman PT.

Gynecol Oncol. 2014 Sep;134(3):546-51. doi: 10.1016/j.ygyno.2014.06.034. Epub 2014 Jul 9.

24.

CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity.

Zhang Q, Schmandt R, Celestino J, McCampbell A, Yates MS, Urbauer DL, Broaddus RR, Loose DS, Shipley GL, Lu KH.

Gynecol Oncol. 2014 Apr;133(1):83-9. doi: 10.1016/j.ygyno.2013.12.006.

25.

Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study.

Daniels MS, Babb SA, King RH, Urbauer DL, Batte BA, Brandt AC, Amos CI, Buchanan AH, Mutch DG, Lu KH.

J Clin Oncol. 2014 Apr 20;32(12):1249-55. doi: 10.1200/JCO.2013.50.6055. Epub 2014 Mar 17.

26.

Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.

Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, Tamboli P, Tannir NM, Wood CG.

Eur Urol. 2014 Nov;66(5):874-80. doi: 10.1016/j.eururo.2014.01.035. Epub 2014 Feb 7.

27.

Outcomes of screening endometrial cancer patients for Lynch syndrome by patient-administered checklist.

Daniels MS, Urbauer DL, Zangeneh A, Batte BA, Dempsey KM, Lu KH.

Gynecol Oncol. 2013 Dec;131(3):619-23. doi: 10.1016/j.ygyno.2013.10.011. Epub 2013 Oct 17.

28.

Randomized controlled trial of a sun protection intervention for children of melanoma survivors.

Gritz ER, Tripp MK, Peterson SK, Prokhorov AV, Shete SS, Urbauer DL, Fellman BM, Lee JE, Gershenwald JE.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1813-24. doi: 10.1158/1055-9965.EPI-13-0249.

29.

Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review.

Hoang AN, Agarwal PK, Walton-Diaz A, Wood CG, Metwalli AR, Kassouf W, Brown GA, Black PC, Urbauer DL, Grossman HB, Dinney CP, Kamat AM.

BJU Int. 2014 May;113(5b):E28-33. doi: 10.1111/bju.12344. Review.

30.

Impact of cardiovascular comorbidity on ovarian cancer mortality.

Shinn EH, Lenihan DJ, Urbauer DL, Basen-Engquist KM, Valentine A, Palmero L, Woods ML, Patel P, Nick AM, Shahzad MM, Stone RL, Golden A, Atkinson E, Lutgendorf SK, Sood AK.

Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2102-9. doi: 10.1158/1055-9965.EPI-13-0625. Epub 2013 Sep 17.

31.

Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer.

Bruegl AS, Djordjevic B, Urbauer DL, Westin SN, Soliman PT, Lu KH, Luthra R, Broaddus RR.

Curr Pharm Des. 2014;20(11):1655-63.

32.

Efficacy and safety of ibutilide for chemical cardioversion of atrial fibrillation and atrial flutter in cancer patients.

Bickford CL, Agarwal R, Urbauer DL, Durand JB, Lenihan DJ.

Am J Med Sci. 2014 Apr;347(4):277-81. doi: 10.1097/MAJ.0b013e31828a7656.

PMID:
23588261
33.

Chemopreventive effects of metformin on obesity-associated endometrial proliferation.

Zhang Q, Celestino J, Schmandt R, McCampbell AS, Urbauer DL, Meyer LA, Burzawa JK, Huang M, Yates MS, Iglesias D, Broaddus RR, Lu KH.

Am J Obstet Gynecol. 2013 Jul;209(1):24.e1-24.e12. doi: 10.1016/j.ajog.2013.03.008. Epub 2013 Mar 15.

34.

Postoperative outcomes after continent versus incontinent urinary diversion at the time of pelvic exenteration for gynecologic malignancies.

Urh A, Soliman PT, Schmeler KM, Westin S, Frumovitz M, Nick AM, Fellman B, Urbauer DL, Ramirez PT.

Gynecol Oncol. 2013 Jun;129(3):580-5. doi: 10.1016/j.ygyno.2013.02.024. Epub 2013 Feb 26.

35.

Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study.

Parker PA, Alba F, Fellman B, Urbauer DL, Li Y, Karam JA, Tannir N, Jonasch E, Wood CG, Matin SF.

Eur Urol. 2013 Jun;63(6):1122-7. doi: 10.1016/j.eururo.2013.01.034. Epub 2013 Feb 9.

36.

Consistency of symptom clusters among advanced cancer patients seen at an outpatient supportive care clinic in a tertiary cancer center.

Yennurajalingam S, Kwon JH, Urbauer DL, Hui D, Reyes-Gibby CC, Bruera E.

Palliat Support Care. 2013 Dec;11(6):473-80. doi: 10.1017/S1478951512000879. Epub 2013 Feb 7.

PMID:
23388652
37.
38.

Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible.

Garg K, Broaddus RR, Soslow RA, Urbauer DL, Levine DA, Djordjevic B.

Int J Gynecol Pathol. 2012 Jan;31(1):48-56. doi: 10.1097/PGP.0b013e3182230d00.

39.

Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing.

Bartley AN, Luthra R, Saraiya DS, Urbauer DL, Broaddus RR.

Cancer Prev Res (Phila). 2012 Feb;5(2):320-7. doi: 10.1158/1940-6207.CAPR-11-0288. Epub 2011 Nov 15.

40.

Prospective evaluation of insulin resistance among endometrial cancer patients.

Burzawa JK, Schmeler KM, Soliman PT, Meyer LA, Bevers MW, Pustilnik TL, Anderson ML, Ramondetta LM, Tortolero-Luna G, Urbauer DL, Chang S, Gershenson DM, Brown J, Lu KH.

Am J Obstet Gynecol. 2011 Apr;204(4):355.e1-7. doi: 10.1016/j.ajog.2010.11.033. Epub 2011 Feb 16.

41.

Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.

Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, Brooks R, Mutch D, Molina A, Sutphen R, Barnes M, Elder J, Teoh D, Powell CB, Choubey V, Blank S, Macdonald HR, Brady MF, Urbauer DL, Bodurka D, Gershenson DM, Lu KH.

Gynecol Oncol. 2011 May 1;121(2):358-63. doi: 10.1016/j.ygyno.2010.12.354. Epub 2011 Jan 28.

42.

Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?

Vineyard MA, Daniels MS, Urbauer DL, Deavers MT, Sun CC, Boerwinkle E, Bodurka DC, Gershenson DM, Crawford J, Lu KH.

Gynecol Oncol. 2011 Feb;120(2):229-32. doi: 10.1016/j.ygyno.2010.10.033. Epub 2010 Dec 3.

PMID:
21126756
43.

Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum.

Schlumbrecht MP, Xie SS, Shipley GL, Urbauer DL, Broaddus RR.

Mod Pathol. 2011 Mar;24(3):453-62. doi: 10.1038/modpathol.2010.211. Epub 2010 Nov 19.

44.

Impact of a palliative care consultation team on cancer-related symptoms in advanced cancer patients referred to an outpatient supportive care clinic.

Yennurajalingam S, Urbauer DL, Casper KL, Reyes-Gibby CC, Chacko R, Poulter V, Bruera E.

J Pain Symptom Manage. 2011 Jan;41(1):49-56. doi: 10.1016/j.jpainsymman.2010.03.017. Epub 2010 Aug 24.

PMID:
20739141
45.

Marginal zone lymphomas: factors that affect the final outcome.

Mazloom A, Medeiros LJ, McLaughlin PW, Reed V, Cabanillas FF, Fayad LE, Pro B, Gonzalez G, Iyengar P, Urbauer DL, Dabaja BS.

Cancer. 2010 Sep 15;116(18):4291-8. doi: 10.1002/cncr.25325.

46.

Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy.

Svatek RS, Fisher MB, Williams MB, Matin SF, Kamat AM, Grossman HB, Nogueras-González GM, Urbauer DL, Dinney CP.

Urology. 2010 Dec;76(6):1419-24. doi: 10.1016/j.urology.2010.02.053. Epub 2010 May 15.

PMID:
20472264
47.

Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.

Meyer LA, Anderson ME, Lacour RA, Suri A, Daniels MS, Urbauer DL, Nogueras-Gonzalez GM, Schmeler KM, Gershenson DM, Lu KH.

Obstet Gynecol. 2010 May;115(5):945-52. doi: 10.1097/AOG.0b013e3181da08d7.

48.

Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria.

Svatek RS, Fisher MB, Matin SF, Kamat AM, Grossman HB, Nogueras-González GM, Urbauer DL, Kennedy KA, Dinney CP.

J Urol. 2010 Mar;183(3):929-34. doi: 10.1016/j.juro.2009.11.038. Epub 2010 Jan 18.

PMID:
20083264
49.

Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression.

Westin SN, Broaddus RR, Deng L, McCampbell A, Lu KH, Lacour RA, Milam MR, Urbauer DL, Mueller P, Pickar JH, Loose DS.

Cancer Biol Ther. 2009 Nov;8(22):2126-35. Epub 2009 Nov 5.

50.

Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer.

Daniels MS, Urbauer DL, Stanley JL, Johnson KG, Lu KH.

Genet Med. 2009 Sep;11(9):624-8. doi: 10.1097/GIM.0b013e3181ab2295.

PMID:
19606053

Supplemental Content

Loading ...
Support Center